Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KLK2-comPAS phase 3 study of pasritamig with or without JNJ-87189401 versus placebo plus best supportive care in late-line metastatic castration-resistant prostate cancer
jRCT2031250341Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of pasritamig and JNJ-87189401 in metastatic castration-resistant prostate cancer (mCRPC) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Overall survival. Started Nov 2025; status: recruiting.
02
Drugs
pasritamigJNJ-87189401
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2031250341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250341.